Drugs / Muraglitazar
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00240383 | May 2002 → Jun 2006 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT00245388 | Apr → Jul 2002 | hyperlipidemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 38 trials · 1 met primary | ||||||
| Phase 3 | NCT00130806 | Sep → Nov 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00106808 | Aug 2005 → Aug 2006 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00094991 | May 2004 → May 2006 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00095030 | Feb 2004 → Mar 2006 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | Met primary |
| Phase 3 | NCT00240370 | Oct 2003 → Mar 2005 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00162175 | Jul 2003 → Nov 2005 | diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00162240 | Jun 2003 → May 2004 | diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00246987 | Jun 2003 → Apr 2004 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muraglitazar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00094991 ↗ |
| Known as | BMS 298585 | “A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes” NCT00130806 ↗2“Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients” NCT00094991 ↗ “BMS-298585 (muraglitazar) alone in combination with pravastatin” NCT00245388 ↗ |
| Known as | BMS-298585-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL186179 ↗ |
| Known as | MK0478 | “MK0478 (muraglitazar)” NCT00130806 ↗ |
| Known as | MURAGLITAZAR CHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL186179 ↗ |
| Action | Activate | “a dual (alpha/gamma) peroxisome proliferator-activated receptor activator” PMID 20368202 ↗ Apr 20092“Peroxisome proliferator-activated receptor gamma agonist” CHEMBL186179 ↗ “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL186179 ↗ |
| Modality | Small molecule | — CHEMBL186179 ↗ |
| Target | PPARA | “Peroxisome proliferator-activated receptor alpha agonist” CHEMBL186179 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL186179 ↗ |